Conditions: Autism Spectrum Disorders Pervasive Developmental Disorders ASD PDD
Keywords: Autism Spectrum Disorders Pervasive Developmental Disorders ASD PDD Oxytocin Syntocinon treatment
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 8
Healthy volunteers: no

Brief summary:
This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectrum disorders in adolescents ages 11-17.

Detailed description:

Arms:
arm 1: Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.

Interventions: intervention 1: Intranasal Oxytocin
Intervention descriptions: intervention 1: None

Protocol document: